[{"data":1,"prerenderedAt":172},["ShallowReactive",2],{"drug-fibrinogen":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":37,"contraindications":63,"warnings":73,"renal":88,"monitoring":89,"interactions":90,"review":91,"examples":94,"atc":100,"iran":102,"links":118,"populations":133,"usApproval":167},"fibrinogen",1,{"fa":7,"en":8},"کنسانتره فیبرینوژن","Fibrinogen concentrate (human)","blood",{"fa":11,"en":12},"فاکتور انعقادی","Coagulation factor",[14],{"name":15,"market":16},"RiaSTAP","US",[18,19,20,21],"riastap","haemocomplettan","فیبرینوژن","هموکمپلتان",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":32,"refs":33},"vial-1g","powder-for-injection","iv","About 1 g vial (actual potency on label)",{"amount":29,"unit":30,"perUnit":31},1000,"mg","vial",[16],[34],{"source":35,"section":36},"fda-riastap","3",[38],{"id":39,"disease":40,"label":41,"population":44,"type":45,"unit":30,"dose":46,"refs":49,"durationDays":52,"notes":53},"unknown","fibrinogen-deficiency",{"fa":42,"en":43},"خونریزی حاد در کمبود مادرزادی فیبرینوژن (سطح نامعلوم) — ۷۰ mg\u002Fkg وریدی آهسته","Acute bleeding in congenital fibrinogen deficiency (level unknown) — 70 mg\u002Fkg slow IV",{},"weightBased",{"perKgPerDose":47,"intervalHours":48},70,24,[50],{"source":35,"section":51},"2.1",{"min":5,"max":5},[54],{"text":55,"refs":58},{"fa":56,"en":57},"سطح معلوم: دوز (mg\u002Fkg) = (سطح هدف − سطح فعلی mg\u002FdL) ÷ ۱٫۷. هدف ۱۰۰ mg\u002FdL تا هموستاز. سرعت حداکثر ۵ mL\u002Fدقیقه.","Known level: dose (mg\u002Fkg) = (target − measured, mg\u002FdL) ÷ 1.7. Target 100 mg\u002FdL until haemostasis. Rate max 5 mL\u002Fmin.",[59,61],{"source":35,"section":60},"2",{"source":35,"section":62},"2.3",[64],{"id":65,"severity":66,"text":67,"refs":70},"hyper","block",{"fa":68,"en":69},"آنافیلاکسی یا واکنش شدید به فرآورده‌های پلاسمای انسانی.","Anaphylactic or severe reactions to human plasma-derived products.",[71],{"source":35,"section":72},"4",[74,81],{"text":75,"refs":78},{"fa":76,"en":77},"واکنش حساسیتی؛ ترومبوز.","Hypersensitivity; thrombosis.",[79],{"source":35,"section":80},"5",{"text":82,"refs":85},{"fa":83,"en":84},"فرآورده مشتق از پلاسمای انسانی — خطر نظری انتقال عوامل عفونی.","Human plasma-derived — theoretical risk of transmitting infectious agents.",[86],{"source":35,"section":87},"5.3",[],[],[],{"status":92,"reviewer":93,"date":93},"unverified",null,[95],{"regimen":39,"formulation":24,"input":96,"expect":98},{"ageYears":97,"weightKg":97},20,{"perDose":99},1400,[101],"B02BB01",{"status":103,"forms":104,"refs":113},"registered",[105,109],{"code":106,"en":107,"fa":108},"00532","FIBRINOGEN 1G VIAL","ویال فیبرینوژن ۱ گرم",{"code":110,"en":111,"fa":112},"16757","FIBRINOGEN\u002FTHROMBIN 5.5MG\u002F2IU TRANSDERMAL PATCH","پچ پوستی فیبرینوژن \u002F ترومبین ۵٫۵ میلی‌گرم \u002F ۲ واحد بین‌المللی",[114],{"source":115,"section":116,"url":117},"darooyab-generic","G-1402\u002FFibrinogen","https:\u002F\u002Fwww.darooyab.ir\u002FG-1402\u002FFibrinogen",[119,123,127,130],{"kind":120,"url":121,"label":122},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=125317","BLA125317",{"kind":124,"url":125,"label":126},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=903dc8d0-39da-462c-9dac-004e0c7a26cc","FDA RiaSTAP",{"kind":128,"url":129,"label":101},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B02BB01",{"kind":131,"url":117,"label":132},"darooyab","Fibrinogen",{"pregnancy":134,"lactation":143,"pediatric":151,"geriatric":159},{"level":135,"text":136,"quote":139,"refs":140},"caution",{"fa":137,"en":138},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no studies of RIASTAP use in pregnant women.",[141],{"source":35,"section":142},"8.1",{"level":135,"text":144,"quote":147,"refs":148},{"fa":145,"en":146},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of RIASTAP in human milk, its effects on the breastfed infant, or its effects on milk production.",[149],{"source":35,"section":150},"8.2",{"level":135,"text":152,"quote":155,"refs":156},{"fa":153,"en":154},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","RIASTAP studies have included subjects below the age of 16 years.",[157],{"source":35,"section":158},"8.4",{"level":135,"text":160,"quote":163,"refs":164},{"fa":161,"en":162},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","The safety and efficacy of RIASTAP in the geriatric population has not been studied.",[165],{"source":35,"section":166},"8.5",{"kind":168,"refs":169,"id":122},"BLA",[170],{"source":35,"section":171},"SPL approval \u002F marketing category",1792444398953]